Understanding broadly neutralizing sarbecovirus antibody responses is key to developing
countermeasures against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …

The recent emergence of SARS-CoV-2 variants of concern,,,,,,,,–and the recurrent spillovers
of coronaviruses, into the human population highlight the need for broadly neutralizing …

The recurrent zoonotic spillover of coronaviruses (CoVs) into the human population
underscores the need for broadly active countermeasures. We employed a directed …

Human monoclonal antibodies (mAbs) that target the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) spike protein have been isolated from convalescent …

Many anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) neutralizing
antibodies target the angiotensin-converting enzyme 2 (ACE2) binding site on viral spike …

An ideal therapeutic anti-SARS-CoV-2 antibody would resist viral escape,–, have activity
against diverse sarbecoviruses,,–, and be highly protective through viral neutralization,,–and …

Potent neutralizing SARS-CoV-2 antibodies often target the spike protein receptor-binding
site (RBS), but the variability of RBS epitopes hampers broad neutralization of multiple …

The emergence of current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variants of concern (VOCs) and potential future spillovers of SARS-like coronaviruses into …

Broadly protective vaccines against known and preemergent human coronaviruses (HCoVs)
are urgently needed. To gain a deeper understanding of cross-neutralizing antibody …

SARS-CoV-2 is a newly emerged coronavirus responsible for the current COVID-19
pandemic that has resulted in more than one million infections and 73,000 deaths,. Vaccine …